阿斯利康制药(AZN.UK)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

AZN.UK 阿斯利康制药

未开盘 11-04 16:30:00 GMT 延时

11,042.00

+20.00

+0.18%

最高11,342.00	最低10,930.00	成交量129.55万
今开11,016.00	昨收11,022.00	日振幅3.74%
总市值17.12万亿	流通市值17.06万亿	总股本15.50亿
成交额143.72亿	换手率0.08%	流通股本15.45亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

{"stockData":{"symbol":"AZN.UK","market":"UK","secType":"STK","nameCN":"阿斯利康制药","latestPrice":11042,"timestamp":1730737800000,"preClose":11022,"halted":0,"volume":1295533,"delay":15,"floatShares":1544833484,"shares":1550303887,"eps":317.89145,"marketStatus":"未开盘","marketStatusCode":0,"change":20,"latestTime":"11-04 16:30:00 GMT 延时","open":11016,"high":11342,"low":10930,"amount":14372250478,"amplitude":0.03738,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":317.89145,"exchange":"LSE","tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1730793600000},"adr":0,"adjPreClose":11022,"adrRate":0,"openAndCloseTimeList":[[1730707200000,1730737800000]],"volumeRatio":0.797259417600887,"nameEN":"ASTRAZENECA PLC","tradeCurrency":"GBX","tradeService":"SETS","exchangeMarketSize":300},"requestUrl":"/m/hq/s/AZN.UK/wiki","defaultTab":"wiki","newsList":[{"id":"2479789916","title":"阿斯利康称其中国业务总裁正接受调查，股价下跌5.2%","url":"https://stock-news.laohu8.com/highlight/detail?id=2479789916","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2479789916?lang=zh_cn&edition=full","pubTime":"2024-10-30 22:09","pubTimestamp":1730297369,"startTime":"0","endTime":"0","summary":"路透10月30日 - 阿斯利康AZN.L周三表示，阿斯利康中国总裁王磊正在中国配合调查。目前尚不清楚王磊是否被中国当局拘留。该制药公司在一份声明中称，\"阿斯利康中国在现任总经理的带领下正常运营\"，但没有提供更多细节。当被问及王磊的下落时，公司发言人只是重申这位高管正在接受调查。中国是仅次于美国的世界第二大药品市场。1352 GMT，阿斯利康股价下跌5.2%。今年9月，中国拘留了阿斯利康的五名现任和前任员工，对他们进行问话。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241030:nL6S3M60I6:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0963555726.SGD","LU0969580561.USD","LU0128525929.USD","LU0052756011.USD","LU0882574055.USD","LU0310799852.SGD","IE00BJJMRZ35.SGD","LU0997586432.USD","03165","LU0661504455.SGD","IE00B2B36J28.USD","LU0266013472.USD","LU0823416689.USD","IE0034235188.USD","LU0158827948.USD","BK5011","LU0211327993.USD","LU0784384876.USD","LU0976567544.SGD","LU0784385840.USD","LU0526926950.USD","LU0211328371.USD","LU0114720955.EUR","LU0792757196.USD","IE00BFTCPJ56.SGD","LU0889566641.SGD","LU0640478417.SGD","IE00B4R5TH58.HKD","LU0957799991.USD","LU0964806797.USD","LU0211326755.USD","LU0496365809.HKD","LU0211326839.USD","LU0545039389.USD","LU0889565080.SGD","IE0009355771.USD","LU0047473722.EUR","LU0203347892.USD","LU0203345920.USD","LU0310800379.SGD","AZN.UK","LU0949170426.SGD","LU0708994859.HKD","LU0557290698.USD","IE00BJT1NW94.SGD","LU0011850046.USD","LU0047473722.SGD","IE0002141913.USD","LU0077335932.USD","LU0757432116.USD"],"gpt_icon":0},{"id":"2477558597","title":"更新版 4-罗氏公开反对收购药品制造商康泰伦特","url":"https://stock-news.laohu8.com/highlight/detail?id=2477558597","media":"路透中文","labels":["Company Corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2477558597?lang=zh_cn&edition=full","pubTime":"2024-10-23 18:22","pubTimestamp":1729678923,"startTime":"0","endTime":"0","summary":"更新版 4-罗氏公开反对收购药品制造商康泰伦特罗氏首席执行官：限制该领域的竞争并非好事 罗氏称受康泰伦特交易影响的不是自己，而是其他公司瑞士制药商与美国同行礼来一起表示反对第 11 和 12 段增加了诺和诺德的评论Ludwig Burger. 路透法兰克福10月23日 - 制药巨头罗氏ROG.S.的首席执行官称，有关部门应阻止诺和诺德的控股股东收购合同药品生产商康泰伦特CTLT.N.，因为这可能会打击蓬勃发展的减肥药行业的竞争。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241023:nL4T3LZ15P:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"Company Corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0289739699.SGD","LU0957799991.USD","LU0058720904.USD","LU0738911758.USD","LU1883839398.USD","LU0345777659.USD","LU0972486137.USD","BK5011","GPCR","CTLT","LU0661504455.SGD","LU0823399737.USD","IE00B19Z3B42.SGD","IE000M9KFDE8.USD","LU0964806797.USD","IE00BJT1NW94.SGD","BK4139","PFE","IE00BJJMRZ35.SGD","VKTX","LU0047473722.EUR","SGXZ57979304.SGD","BK4533","IE00BFTCPJ56.SGD","LU0868494617.USD","BK4530","BK4550","LU0882574055.USD","SG9999001176.USD","LU0211327993.USD","LU0557290698.USD","AMGN","LU1066051498.USD","LU0553294199.USD","BK4566","LU0310800965.SGD","BK4007","LU1061106388.HKD","LU0321505868.SGD","LU0757432116.USD","LU0211328371.USD","IE00BLSP4452.SGD","LU0211326755.USD","LU0784385840.USD","AZN.UK","LU0122379950.USD","LU1066053197.SGD","SG9999002224.SGD","03165","SG9999013999.USD"],"gpt_icon":1},{"id":"2477558594","title":"更新版 4-罗氏公开反对收购药品制造商康泰伦特","url":"https://stock-news.laohu8.com/highlight/detail?id=2477558594","media":"路透中文","labels":["Company Corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2477558594?lang=zh_cn&edition=full","pubTime":"2024-10-23 18:22","pubTimestamp":1729678923,"startTime":"0","endTime":"0","summary":"更新版 4-罗氏公开反对收购药品制造商康泰伦特罗氏首席执行官：限制该领域的竞争并非好事 罗氏称受康泰伦特交易影响的不是自己，而是其他公司瑞士制药商与美国同行礼来一起表示反对第 11 和 12 段增加了诺和诺德的评论Ludwig Burger. 路透法兰克福10月23日 - 制药巨头罗氏ROG.S.的首席执行官称，有关部门应阻止诺和诺德的控股股东收购合同药品生产商康泰伦特CTLT.N.，因为这可能会打击蓬勃发展的减肥药行业的竞争。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241023:nL4S3LZ15P:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"Company Corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4566","LU1883839398.USD","AMGN","LU0661504455.SGD","VKTX","LU0868494617.USD","CTLT","LU0211326755.USD","IE00B19Z3B42.SGD","LU0321505868.SGD","LU0757432116.USD","LU0823399737.USD","IE00BJJMRZ35.SGD","AZN.UK","IE00BFTCPJ56.SGD","LU0964806797.USD","LU0047473722.EUR","LU0553294199.USD","SG9999001176.USD","LU1061106388.HKD","LU0957799991.USD","BK4533","LU0557290698.USD","LU0784385840.USD","LU1066051498.USD","BK5011","LU0211327993.USD","SG9999002224.SGD","IE00BLSP4452.SGD","SG9999013999.USD","LU0289739699.SGD","BK4139","03165","LU0972486137.USD","LU1066053197.SGD","SGXZ57979304.SGD","LU0310800965.SGD","LU0058720904.USD","PFE","LU0882574055.USD","IE00BJT1NW94.SGD","LU0345777659.USD","LU0122379950.USD","IE000M9KFDE8.USD","GPCR","BK4550","LU0738911758.USD","BK4530","LU0211328371.USD","BK4007"],"gpt_icon":1},{"id":"2477539245","title":"更新版 3-罗氏公开反对收购药品制造商康泰伦特","url":"https://stock-news.laohu8.com/highlight/detail?id=2477539245","media":"路透中文","labels":["Company Corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2477539245?lang=zh_cn&edition=full","pubTime":"2024-10-23 18:22","pubTimestamp":1729678923,"startTime":"0","endTime":"0","summary":"更新版 3-罗氏公开反对收购药品制造商康泰伦特罗氏首席执行官：限制该领域的竞争并非好事 罗氏称受康泰伦特交易影响的不是自己，而是其他公司瑞士制药商与美国同行礼来一起表示反对第 6 段增加了首席执行官的评论，第 13 段增加了康泰伦特的评论Ludwig Burger. 路透法兰克福10月23日 - 制药巨头罗氏ROG.S.的首席执行官说，有关部门应该阻止诺和诺德的控股股东收购合同药品生产商康泰伦特CTLT.N.，因为这可能会打击蓬勃发展的减肥药行业的竞争。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241023:nL4S3LZ15P:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"Company Corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4566","LU0203347892.USD","LU0823416689.USD","LU0708994859.HKD","IE00B2B36J28.USD","LU0321505439.SGD","LU0114720955.EUR","LU0969580561.USD","LU0792757196.USD","LU0128525689.USD","LU0052756011.USD","LU0949170772.SGD","LU0128525929.USD","LU0310800379.SGD","LU0972486137.USD","LU0557290698.USD","LU0109394709.USD","GPCR","03165","LU0011850046.USD","LU0122379950.USD","LU0211327993.USD","LU0203345920.USD","IE0002141913.USD","IE000M9KFDE8.USD","LU0170899867.USD","LU0345777659.USD","AZN.UK","BK4568","CTLT","SG9999002232.USD","LU0949170426.SGD","BK4007","IE00BJT1NW94.SGD","LU1057294990.SGD","LU0211326755.USD","LU0225284248.USD","LU0234572021.USD","AMGN","IE00BJJMRZ35.SGD","BK4530","LU0963555726.SGD","VKTX","BK4139","LU0320765992.SGD","BK5011","PFE","LU0985481810.HKD","LU1061106388.HKD","LU0526926950.USD"],"gpt_icon":1},{"id":"2476295343","title":"更新版 2-FDA 批准安斯泰来公司的胃癌疗法","url":"https://stock-news.laohu8.com/highlight/detail?id=2476295343","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2476295343?lang=zh_cn&edition=full","pubTime":"2024-10-19 00:45","pubTimestamp":1729269925,"startTime":"0","endTime":"0","summary":"路透10月18日 - 美国食品和药物管理局网站周五显示，该局批准了安斯泰来公司用于治疗一种胃癌的4503.T疗法。据美国癌症协会称，胃癌约占美国每年新诊断癌症总数的 1.5%。安斯泰来公司没有立即回应路透关于该疗法定价 和供应细节的 请求。该疗法于今年 3 月在日本获批，成为全球首个获批的针对胃癌中常见的一种与癌细胞结合的蛋白质家族的靶向疗法。美国食品和药物管理局此前曾拒绝批准该疗法，理由是与第三方制造商 。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241018:nL4S3LU1LD:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4534","IE00BBT3K403.USD","IE00BN8TJ469.HKD","LU0823399737.USD","LU0289739699.SGD","LU0640478417.SGD","03165","LU0545039389.USD","LU0965509101.SGD","LU0158827948.USD","LU0128525689.USD","IE00BSNM7G36.USD","LU0211326755.USD","LU0661504455.SGD","LU0106261372.USD","LU0964806797.USD","LU1057294990.SGD","LU0972486137.USD","AZN.UK","LU0077335932.USD","LU0234572021.USD","LU1934455277.USD","LU0965509283.SGD","LU0345777659.USD","LU1037948541.HKD","MRK","IE00BLSP4452.SGD","LU0006306889.USD","LU0784384876.USD","LU1585245621.USD","LU1093756168.USD","LU0029864427.USD","LU0266013472.USD","LU0052756011.USD","LU0792757196.USD","BK4533","LU0211326839.USD","LU0238689110.USD","LU1291159041.SGD","LU1934455194.USD","LU0738911758.USD","LU0208291251.USD","LU1023059063.AUD","IE00BLSP4239.USD","IE00BJT1NW94.SGD","LU0949170426.SGD","LU0047473722.SGD","LU1037948897.HKD","IE00B1BXHZ80.USD","LU0949170772.SGD"],"gpt_icon":0},{"id":"2476420800","title":"更正-默克公司用于婴儿的 RSV 抗体在研究中能有效减少某些类型的感染 (10 月 17 日)","url":"https://stock-news.laohu8.com/highlight/detail?id=2476420800","media":"路透中文","labels":["Product Release"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2476420800?lang=zh_cn&edition=full","pubTime":"2024-10-18 06:00","pubTimestamp":1729202406,"startTime":"0","endTime":"0","summary":"更正-默克公司用于婴儿的 RSV 抗体在研究中能有效减少某些类型的感染 更正了10月17日报导中的标题、第1段和第2段，以显示该药可减少药物引起的下呼吸道感染，而不是所有的下呼吸道感染。路透10月18日 - 默克公司MRK.N周四称，其实验性抗体疗法克雷索单抗在减少某些类型的婴儿呼吸道合胞病毒 相关感染方面的有效率为60.4%。默克公司表示，与安慰剂相比，该药还有助于将RSV相关住院率降低84.2%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241017:nL4T3LT1XM:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Product Release","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999002232.USD","BK4534","LU0058720904.USD","LU0203347892.USD","LU0557290698.USD","AZN.UK","LU0128525929.USD","LU0957799991.USD","LU0757432116.USD","IE00BJJMRZ35.SGD","SG9999002224.SGD","LU0310800965.SGD","LU0265550359.USD","LU0047473722.SGD","LU0985481810.HKD","LU0011850046.USD","BK4533","LU0211326755.USD","LU1883839398.USD","LU1934455863.HKD","IE00BFTCPJ56.SGD","MRK","LU0225284248.USD","SG9999001176.USD","LU0823416689.USD","LU1066053197.SGD","SG9999001176.SGD","LU0496365809.HKD","LU0882574055.USD","LU1093756325.SGD","IE00BBT3K403.USD","LU1066051225.USD","LU0553294199.USD","LU1066051498.USD","LU0310799852.SGD","LU0047473722.EUR","LU0997586432.USD","LU1894683264.USD","03165","LU0345777147.USD","LU0321505868.SGD","LU0320765489.SGD","LU0211328371.USD","LU0006306889.USD","LU0784385840.USD","LU0203345920.USD","LU0306807586.USD","BK4581","LU0171293334.USD"],"gpt_icon":1},{"id":"2473465219","title":"《股市简讯》中国石药集团一度升10%，将向阿斯利康收取1亿美元预付款","url":"https://stock-news.laohu8.com/highlight/detail?id=2473465219","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2473465219?lang=zh_cn&edition=full","pubTime":"2024-10-08 09:23","pubTimestamp":1728350597,"startTime":"0","endTime":"0","summary":"《股市简讯》中国石药集团一度升10%，将向阿斯利康收取1亿美元预付款* 中国石药集团1093.HK周二早盘一度劲升10%，但之后转跌，将就专利授权交易向阿斯利康收取1亿美元预付款* 香港恒生指数.HSI下跌4%。* 石药集团称，与AstraZenecaAZN.L订立独家授权协议，以在全球开发、制造及商业化本集团的脂蛋白抑制剂YS2302018。公司称，本集团将收取1亿美元的预付款，并有权收取最高3.7亿美元的潜在开发里程碑付款及最高15.5亿美元的潜在销售里程碑付款。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241008:nL4T3LK03J:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0072913022.USD","LU1829250122.USD","01093","LU0047473722.SGD","LU0880133367.SGD","LU0640478417.SGD","LU0211326839.USD","LU1152091168.USD","LU2417539215.USD","LU1993786604.SGD","LU0949170772.SGD","LU0964806797.USD","LU1152091754.HKD","LU0266013472.USD","IE00BJT1NW94.SGD","LU0792757196.USD","LU0949170426.SGD","LU1226287529.USD","LU0158827948.USD","IE0008369823.USD","LU1008478684.HKD","LU0128525689.USD","LU0203347892.USD","LU0972486137.USD","IE00B5MMRT66.SGD","AZN.UK","IE0008368742.USD","AZN","IE00B4R5TH58.HKD","IE00B2B36J28.USD","LU0211326755.USD","LU0320765992.SGD","LU0661504455.SGD","LU0784384876.USD","LU0345777659.USD","LU2236285917.USD","LU0738911758.USD","LU1226288170.HKD","LU1226287875.USD","LU0976567544.SGD","LU1226287792.SGD","03165","IE00B543WZ88.USD","LU0077335932.USD","LU1807302812.USD","BK1521","LU0029864427.USD","LU0823399737.USD","LU0052756011.USD","LU0545039389.USD"],"gpt_icon":0},{"id":"2473388024","title":"Cboe 将上市 Precidian 开发的对冲 ADRs","url":"https://stock-news.laohu8.com/highlight/detail?id=2473388024","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2473388024?lang=zh_cn&edition=full","pubTime":"2024-10-08 03:21","pubTimestamp":1728328869,"startTime":"0","endTime":"0","summary":"Cboe 将上市 Precidian 开发的对冲 ADRsLaura Matthews路透纽约10月7日 - Precidian Investments 周一推出了对冲美国存托凭证，美国投资者可以用它来购买外国上市的股票，同时限制 货币波动的影响 。但 Cboe 表示，通过将 ADR 与货币覆盖合并为一种证券，投资者可以减轻货币风险。\"Cboe ETP 上市业务全球主管 Rob Marrocco 告诉路透：\"对于美国投资者来说，这确实是下一代 ADR。该产品将被称为 ADRhedged。Cboe 的美国股票交易所将首先上市阿斯利康AZN.L ADRhedged、汇丰控股HSBA.L ADRhedged 和壳牌SHEL.L ADRhedged，预计不久将再增加 14 家。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241007:nL4T3LJ1DI:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0557290698.USD","LU0526926950.USD","LU0225283273.USD","LU0889566641.SGD","LU0965509010.AUD","LU0345781412.USD","LU0211328371.USD","LU0307460666.USD","03165","LU0965508806.USD","BK4588","LU0588546209.SGD","LU1019632923.USD","LU0171293334.USD","SHEL.UK","LU0550127509.SGD","LU0823416689.USD","HSBA.UK","IE0009355771.USD","LU0540923850.HKD","LU0114720955.EUR","LU0289941410.SGD","LU0969580561.USD","LU0310800379.SGD","LU0175139822.USD","LU1668664300.SGD","LU0162691827.USD","LU0757432116.USD","LU0976567544.SGD","LU0784385840.USD","IE0034235071.USD","LU0963555726.SGD","IE00BFTCPJ56.SGD","LU0149721374.USD","LU0957799991.USD","IE00B4R5TH58.HKD","LU0048584097.USD","LU0011850046.USD","LU0861579265.USD","BK5011","IE00B2B36J28.USD","BK4585","CBOE","LU0203345920.USD","LU0310800965.SGD","LU0310799852.SGD","LU0496365809.HKD","LU0047473722.EUR","LU1481107354.HKD","AZN.UK"],"gpt_icon":0},{"id":"2470424374","title":"更新版 4-安进公司肌肉疾病药物在后期研究中达到主要目标","url":"https://stock-news.laohu8.com/highlight/detail?id=2470424374","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2470424374?lang=zh_cn&edition=full","pubTime":"2024-09-25 04:51","pubTimestamp":1727211060,"startTime":"0","endTime":"0","summary":"更新版 4-安进公司肌肉疾病药物在后期研究中达到主要目标安进公司的 Uplizna 在治疗肌肉萎缩的研究中获得成功分析师称另一种实验性药物的数据不具 \"竞争力 数据参差不齐，股价在延时交易中下跌 2 第 4、10 和 11 段增加了分析师评论，第 3、8 和 9 段增加了试验数据，第 6 段增加了执行评论Bhanvi Satija/Puyaan Singh. 路透9月24日 - 安进公司AMGN.O周二表示，其药物有助于改善一种罕见肌肉衰弱疾病患者的咀嚼和吞咽等日常活动，达到了一项后期研究的主要目标。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20240924:nL4T3L61W4:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0889565080.SGD","IE00B2B36J28.USD","LU0957799991.USD","IE00B4R5TH58.HKD","LU0011850046.USD","BK5011","LU0310800379.SGD","IE0009355771.USD","LU0109394709.USD","LU0963555726.SGD","LU0889566641.SGD","BK4139","LU0047473722.EUR","REGN","IE0002141913.USD","LU2112291526.USD","LU0171293334.USD","IE00BFTCPJ56.SGD","LU0526926950.USD","LU0889565916.HKD","LU0976567544.SGD","LU0114720955.EUR","LU0310799852.SGD","LU0557290698.USD","AMGN","LU0052756011.USD","LU2362541513.USD","LU0553294199.USD","BK4566","LU2242652126.USD","LU0310800965.SGD","BK4581","LU0823416689.USD","LU1061106388.HKD","LU0757432116.USD","LU0969580561.USD","LU2362541273.HKD","LU0211328371.USD","LU2023250504.SGD","LU0784385840.USD","BK4585","IE0034235188.USD","LU1917777945.USD","AZN.UK","LU0496365809.HKD","LU0640478417.SGD","LU0203345920.USD","03165","LU1974910355.USD","BK4588"],"gpt_icon":0},{"id":"2470069440","title":"更新版 3-安进公司肌肉疾病药物在后期研究中达到主要目标","url":"https://stock-news.laohu8.com/highlight/detail?id=2470069440","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2470069440?lang=zh_cn&edition=full","pubTime":"2024-09-25 04:51","pubTimestamp":1727211060,"startTime":"0","endTime":"0","summary":"更新版 3-安进公司肌肉疾病药物在后期研究中达到主要目标在第7-10段增加公司药物uplinza的背景介绍。路透9月24日 - 安进公司AMGN.O周二表示，该公司的药物有助于改善一种罕见肌肉衰弱疾病患者的咀嚼和吞咽等日常活动，达到了一项后期研究的主要目标。另外，该制药公司还表示，其实验性药物罗卡替尼在一项后期研究中达到了主要目标和次要目标，该研究测试了罗卡替尼作为特应性皮炎这种炎症性皮肤病治疗药物的效果。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20240924:nL4T3L61W4:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0128525929.USD","SG9999001440.SGD","LU0964806797.USD","LU0266013472.USD","BK4566","03165","LU0077335932.USD","LU0640478417.SGD","LU0889565916.HKD","LU0889566641.SGD","LU0345777147.USD","LU0320765992.SGD","LU0823399737.USD","LU0047473722.SGD","LU0211326839.USD","LU0661504455.SGD","LU0868494617.USD","AMGN","LU1571399168.USD","BK4534","LU1983299246.USD","LU0052756011.USD","LU1023059063.AUD","IE00B2B36J28.USD","LU0738911758.USD","BK4533","LU1057294990.SGD","LU0545039389.USD","LU2242646821.SGD","IE00B4R5TH58.HKD","LU0949170772.SGD","LU0345777659.USD","LU0211326755.USD","AZN.UK","LU0823416689.USD","LU0997586432.USD","LU0289739699.SGD","LU0203347892.USD","IE00BJT1NW94.SGD","LU0784384876.USD","LU0058720904.USD","LU0976567544.SGD","LU0122379950.USD","LU0128525689.USD","LU0949170426.SGD","BK4585","LU0972486137.USD","LU0158827948.USD","LU0792757196.USD","LU0029864427.USD"],"gpt_icon":0},{"id":"2446334739","title":"阿斯利康中国：中国国家药监局批准泰瑞沙联合化疗治疗肺癌","url":"https://stock-news.laohu8.com/highlight/detail?id=2446334739","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2446334739?lang=zh_cn&edition=full","pubTime":"2024-06-26 14:55","pubTimestamp":1719384922,"startTime":"0","endTime":"0","summary":"阿斯利康中国：中国国家药监局批准泰瑞沙联合化疗治疗肺癌","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20240626:nL4T3IO0G1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_zh_live","symbols":["LU0889565080.SGD","LU0738911758.USD","LU1481600234.SGD","LU0011850046.USD","LU0792757196.USD","LU0972486137.USD","IE0009355771.USD","LU0211326839.USD","LU0784384876.USD","LU0109394709.USD","LU0963555726.SGD","LU1291159041.SGD","IE00BJJMRZ35.SGD","BK4568","LU0047473722.EUR","LU1481599808.USD","LU0949170772.SGD","LU0171293334.USD","IE00BFTCPJ56.SGD","LU0526926950.USD","LU0949170426.SGD","LU0889565916.HKD","LU0976567544.SGD","LU0114720955.EUR","LU1267930813.SGD","LU0310799852.SGD","LU0211327993.USD","LU0557290698.USD","LU1487256676.USD","LU0052756011.USD","LU1496350171.SGD","LU1019634622.SGD","LU1814569148.SGD","LU1989772840.SGD","AZN","LU0047473722.SGD","LU2236285917.USD","LU0128525689.USD","LU0969580561.USD","LU0211328371.USD","LU1496350502.SGD","LU0158827948.USD","LU0266013472.USD","IE0034235188.USD","AZN.UK","LU0496365809.HKD","LU0640478417.SGD","LU1989771016.USD","03165","LU1019632923.USD"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.astrazeneca.com","stockEarnings":[{"period":"1week","weight":-0.0504},{"period":"1month","weight":-0.0593},{"period":"3month","weight":-0.1046},{"period":"6month","weight":-0.0941},{"period":"1year","weight":0.0988},{"period":"ytd","weight":0.0645}],"compareEarnings":[{"period":"1week","weight":-0.0117},{"period":"1month","weight":-0.0097},{"period":"3month","weight":0.0305},{"period":"6month","weight":-0.0033},{"period":"1year","weight":0.1438},{"period":"ytd","weight":0.0904}],"compareStock":{"symbol":"ISF.UK","name":"FTSE100 ETF"},"description":"阿斯利康股份有限公司于1992年6月17日根据1985年《公司法》在英格兰和威尔士注册成立。该公司是在1993年将Imperial化学工业公司的制药、农化和特种化学品业务分拆时成立的。1999年，公司出售了特种化学品业务。同样在1999年，该公司与瑞典Astra公司合并。2000年，该公司将农化业务分拆，并将其与诺华公司的同类业务合并，成立了一家新的公司Syngenta AG。2007年，集团收购了位于美国的生物制剂和疫苗企业MedImmune。2021年，集团收购了位于美国的罕见病企业Alexion。","yearOnYearQuotes":[{"month":1,"riseRate":0.451613,"avgChangeRate":-0.001616},{"month":2,"riseRate":0.354839,"avgChangeRate":-0.00963},{"month":3,"riseRate":0.580645,"avgChangeRate":0.031821},{"month":4,"riseRate":0.677419,"avgChangeRate":0.027019},{"month":5,"riseRate":0.580645,"avgChangeRate":0.008233},{"month":6,"riseRate":0.5,"avgChangeRate":0.020988},{"month":7,"riseRate":0.65625,"avgChangeRate":0.012358},{"month":8,"riseRate":0.4375,"avgChangeRate":0.010174},{"month":9,"riseRate":0.625,"avgChangeRate":0.000651},{"month":10,"riseRate":0.53125,"avgChangeRate":0.008917},{"month":11,"riseRate":0.46875,"avgChangeRate":0.004461},{"month":12,"riseRate":0.580645,"avgChangeRate":0.007055}],"exchange":"LSE","name":"阿斯利康制药","nameEN":"ASTRAZENECA PLC"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"阿斯利康制药(AZN.UK)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供阿斯利康制药(AZN.UK)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"阿斯利康制药,AZN.UK,阿斯利康制药股票,阿斯利康制药股票老虎,阿斯利康制药股票老虎国际,阿斯利康制药行情,阿斯利康制药股票行情,阿斯利康制药股价,阿斯利康制药股市,阿斯利康制药股票价格,阿斯利康制药股票交易,阿斯利康制药股票购买,阿斯利康制药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"阿斯利康制药(AZN.UK)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供阿斯利康制药(AZN.UK)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}